Gratus Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $294K | Sell |
7,086
-266
| -4% | -$11.9K | 0.01% | 310 |
|
|
2024
Q1 | $399K | Buy |
7,352
+559
| +8% | +$28.5K | 0.02% | 250 |
|
|
2023
Q4 | $349K | Sell |
6,793
-491
| -7% | -$25.8K | 0.02% | 211 |
|
|
2023
Q3 | $423K | Buy |
7,284
+491
| +7% | +$30.1K | 0.03% | 187 |
|
|
2023
Q2 | $434K | Buy |
6,793
+199
| +3% | +$13.3K | 0.03% | 186 |
|
|
2023
Q1 | $457K | Sell |
6,594
-6,924
| -51% | -$488K | 0.03% | 163 |
|
|
2022
Q4 | $973K | Sell |
13,518
-445
| -3% | -$33.6K | 0.08% | 131 |
|
|
2022
Q3 | $993K | Buy |
13,963
+7,341
| +111% | +$533K | 0.11% | 114 |
|
|
2022
Q2 | $510K | Buy |
6,622
+990
| +18% | +$75.4K | 0.06% | 134 |
|
|
2022
Q1 | $411K | Sell |
5,632
-196
| -3% | -$13.2K | 0.04% | 158 |
|
|
2021
Q4 | $363K | Sell |
5,828
-666
| -10% | -$39.1K | 0.03% | 162 |
|
|
2021
Q3 | $384K | Buy |
6,494
+313
| +5% | +$20.6K | 0.04% | 149 |
|
|
2021
Q2 | $413K | Sell |
6,181
-48
| -0.8% | -$3.13K | 0.05% | 146 |
|
|
2021
Q1 | $393K | Sell |
6,229
-430
| -6% | -$26.8K | 0.05% | 147 |
|
|
2020
Q4 | $413K | Sell |
6,659
-620
| -9% | -$38.1K | 0.06% | 138 |
|
|
2020
Q3 | $439K | Sell |
7,279
-1,725
| -19% | -$104K | 0.07% | 127 |
|
|
2020
Q2 | $529K | Buy |
9,004
+921
| +11% | +$55.1K | 0.09% | 116 |
|
|
2020
Q1 | $451K | Sell |
8,083
-50
| -0.6% | -$3.06K | 0.08% | 122 |
|
|
2019
Q4 | $522K | Sell |
8,133
-77
| -0.9% | -$4.41K | 0.08% | 131 |
|
|
2019
Q3 | $416K | Sell |
8,210
-750
| -8% | -$35.2K | 0.07% | 134 |
|
|
2019
Q2 | $406K | Sell |
8,960
-8,500
| -49% | -$396K | 0.07% | 136 |
|
|
2019
Q1 | $833K | Sell |
17,460
-300
| -2% | -$14.9K | 0.14% | 113 |
|
|
2018
Q4 | $923K | Sell |
17,760
-450
| -2% | -$24.2K | 0.19% | 108 |
|
|
2018
Q3 | $1.13M | Sell |
18,210
-740
| -4% | -$43.9K | 0.15% | 99 |
|
|
2018
Q2 | $1.05M | Sell |
18,950
-200
| -1% | -$10.8K | 0.16% | 98 |
|
|
2018
Q1 | $1.21M | Buy |
19,150
+75
| +0.4% | +$4.83K | 0.17% | 99 |
|
|
2017
Q4 | $1.17M | Sell |
19,075
-400
| -2% | -$25K | 0.15% | 105 |
|
|
2017
Q3 | $1.24M | Sell |
19,475
-115
| -0.6% | -$6.71K | 0.17% | 100 |
|
|
2017
Q2 | $1.09M | Buy |
19,590
+354
| +2% | +$19.3K | 0.16% | 104 |
|
|
2017
Q1 | $1.05M | Buy |
19,236
+143
| +0.7% | +$7.84K | 0.15% | 105 |
|
|
2016
Q4 | $1.12M | Buy |
19,093
+104
| +0.5% | +$5.69K | 0.17% | 100 |
|
|
2016
Q3 | $1.02M | Buy |
18,989
+397
| +2% | +$25.5K | 0.15% | 103 |
|
|
2016
Q2 | $1.37M | Buy |
+18,592
| New | +$1.31M | 0.2% | 94 |
|
Other funds holding BMY
Gratus Capital's BMY Position: Q2 2024 in Review
Gratus Capital reduced its Bristol-Myers Squibb (BMY) stake by 3.6% in Q2 2024, selling an estimated $11.9K and leaving 7,086 shares worth $294K. The position accounts for 0.01% of the portfolio, ranked #310.
Gratus Capital first reported a position in BMY in Q2 2016 and has held it in 33 quarters since. The position peaked at $1.37M in Q2 2016. 2,147 funds tracked by Wall St. Rank hold BMY as of Q2 2024.
- Gratus Capital held 7,086 shares of Bristol-Myers Squibb worth $294K as of Q2 2024.
- Gratus Capital sold 266 Bristol-Myers Squibb shares in Q2 2024, an estimated $11.9K.
- Bristol-Myers Squibb made up 0.01% of Gratus Capital's portfolio in Q2 2024, its #310 holding.
- Gratus Capital first reported a position in Bristol-Myers Squibb in Q2 2016 and has held it in 33 quarters since.
- Gratus Capital's Bristol-Myers Squibb position peaked at $1.37M in Q2 2016.
- 2,147 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.
Based on Gratus Capital's 13F filing for Q2 2024, filed 25 Jul 2024.